For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 495,566 | 105,927 | 1,199,955 | 344,035 |
| Professional fees | 70,835 | 234,025 | 38,533 | 43,625 |
| Revenue | - | - | - | 0 |
| Officers salary | 192,398 | 313,965 | 186,157 | 186,197 |
| Research and development | 66,701 | 68,751 | 9,243 | 63,888 |
| Total operating expenses | 825,500 | 722,668 | 1,433,888 | 637,745 |
| Loss on sale of gold | - | -40,911* | 98,427 | 62,469 |
| Loss from operations | -825,500 | -722,668 | -1,433,888 | -637,745 |
| Net change in unrealized depreciation on investment in gold bullion | -20,408 | -114,137* | 30,968 | 10,011 |
| Interest expense | 148,433 | 144,120 | 144,255 | 141,986 |
| Impairment of right-of-use asset | - | - | - | 0 |
| Interest income | 10,805 | 5,941 | 1,118 | 1,140 |
| Total other income/(expenses) | -117,220 | -64,953 | -75,678 | -88,388 |
| Net (loss) before provision for income taxes | -942,720 | -787,621 | -1,509,566 | -726,133 |
| Provision for income taxes | - | - | - | 0 |
| Net (loss) | -942,720 | -787,621 | -1,509,566 | -726,133 |
| Basic EPS | 0 | -0.001 | 0 | 0 |
| Diluted EPS | 0 | -0.001 | 0 | 0 |
| Basic Average Shares | 1,090,869,198 | 1,080,726,913 | 1,068,264,462 | 1,047,493,242 |
| Diluted Average Shares | 1,090,869,198 | 1,080,726,913 | 1,068,264,462 | 1,047,493,242 |
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)